uniQure Announces Update on U.S. Phase I/II Clinical Trial
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline...
Stay updated with breaking news from Tom Malone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline...
Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL BehringLEXINGTON, Mass. and AMSTERDAM, June 20, 2023 -- uniQure N.V. , a leading gene therapy company advancing... | June 20, 2023
LEXINGTON, Mass. and AMSTERDAM, June 16, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced
SALES: British buyers boost business at Goffs Arkle Sale 2023-06-13
One of the most beloved families on Gogglebox is taking a break from the show this summer.